Varenicline is a smoking cessation drug that blocks alveolar expansion in mice intratracheally administrated porcine pancreatic elastase

J Pharmacol Sci. 2018 Jun;137(2):224-229. doi: 10.1016/j.jphs.2018.06.007. Epub 2018 Jun 20.

Abstract

Smoking cessation is the most effective treatment in patients with emphysema and lung inflammation. The aim of the present study was to examine the effect of varenicline, a smoking cessation drug, on emphysema in porcine pancreatic elastase (PPE)-inhaled mice. PPE-inhaled mice were treated with varenicline and an α7 nicotinic acetylcholine receptor (nAChR) antagonist, methyllycaconitine (MLA) for 5 and 21 days. Varenicline markedly ameliorated alveolar expansion and inflammatory response in bronchoalveolar lavage fluid in PPE-inhaled mice. These blocking effects were inhibited by MLA. Our findings demonstrate that varenicline likely has an anti-inflammatory property including reduced inflammatory cell recruitment in lung tissue to protect PPE-induced alveolar expansion via α7 nAChR.

Keywords: Emphysema; Inflammatory cells; Varenicline.

MeSH terms

  • Aconitine / analogs & derivatives
  • Aconitine / pharmacology
  • Aconitine / therapeutic use
  • Administration, Inhalation
  • Animals
  • Anti-Inflammatory Agents
  • Bronchoalveolar Lavage Fluid
  • Disease Models, Animal
  • Emphysema / chemically induced*
  • Emphysema / drug therapy*
  • Emphysema / pathology
  • Mice, Inbred C57BL
  • Nicotinic Agonists*
  • Pancreatic Elastase / administration & dosage
  • Pancreatic Elastase / adverse effects*
  • Pulmonary Alveoli / drug effects*
  • Pulmonary Alveoli / pathology*
  • Smoking Cessation*
  • Varenicline / pharmacology*
  • Varenicline / therapeutic use*
  • alpha7 Nicotinic Acetylcholine Receptor / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents
  • Nicotinic Agonists
  • alpha7 Nicotinic Acetylcholine Receptor
  • methyllycaconitine
  • Pancreatic Elastase
  • Varenicline
  • Aconitine